Study Stopped
Due to a time conflict in the research, the project research has been temporarily suspended.
The Role and Mechanism of Immune Regulation in Acute Lung Injury in Children
1 other identifier
observational
N/A
0 countries
N/A
Brief Summary
Acute lung injury is a highly prevalent disease in children, posing a serious threat to their health and causing economic burden on society and families. It has received high attention. Blocking the cascade immune inflammatory response that occurs in the respiratory tract and finding key targets for the prevention and treatment of acute lung injury has become an important challenge faced by the medical community. The pathogenesis of acute lung injury is complex, involving the combined action of multiple cells and cytokines in the immune system. Therefore, it is necessary to further study the function of immune cells and specific immune pathogenesis, providing new ideas and theoretical basis for clinical treatment of acute lung injury. The omics technology includes Genomics, Transcriptome, proteomics, metabolomics, etc. Through qualitative and quantitative analysis of changes in low molecular weight molecules or metabolites of biological samples, it provides a new way to find biomarkers and pathogenesis. We plan to study the peripheral blood of children with acute lung injury and healthy children, and use network analysis to screen for differential genes and related enrichment pathways in acute lung injury. We aim to explore the correlation between immune regulation and inflammatory repair in children with acute lung injury, and analyze the regulatory mechanisms between immune cells related to it. Provide assistance for clinical diagnosis and treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started May 2023
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 2, 2023
CompletedStudy Start
First participant enrolled
May 2, 2023
CompletedFirst Posted
Study publicly available on registry
May 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2026
CompletedJuly 11, 2023
July 1, 2023
3.1 years
February 2, 2023
July 9, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Degree of inflammation in acute lung injury through measure physiological parameter
The degree of inflammation includes changes in patient inflammatory indicators through measure physiological parameter.
an average of 1week
Secondary Outcomes (1)
Expression of differential genes and proteins through gene sequencing
an average of 1week
Study Arms (2)
experimental group
meeting the specific diagnostic criteria for acute Lung Injury
control group
Healthy children
Interventions
Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
Eligibility Criteria
Children aged 1-14 who were hospitalized in the Children's Hospital affiliated to Chongqing Medical University.
You may qualify if:
- Clinical diagnosis of ALI/ARDS.
You may not qualify if:
- Patients with hemodynamic instability
- Patients with pulmonary hypertension
- Patients with congenital heart disease, congenital genetic metabolic disease, epilepsy, acute and chronic renal insufficiency, nephrotic syndrome, diabetes, etc.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Kumar V. Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury. Front Immunol. 2020 Aug 4;11:1722. doi: 10.3389/fimmu.2020.01722. eCollection 2020.
PMID: 32849610BACKGROUND
Related Links
Biospecimen
Collect blood, sputum or alveolar lavage fluid samples of subjects, extract RNA or DNA for relevant tests.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zhou Mi, Master
Chongqing Medical University
- PRINCIPAL INVESTIGATOR
Ding Fengxia, Doctor
Chongqing Medical University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- attending doctor
Study Record Dates
First Submitted
February 2, 2023
First Posted
May 17, 2023
Study Start
May 2, 2023
Primary Completion
May 30, 2026
Study Completion
May 30, 2026
Last Updated
July 11, 2023
Record last verified: 2023-07